Circassia snaps at Merck's heels with ragweed vaccine
This article was originally published in Scrip
Executive Summary
Circassia has successfully completed a large-scale Phase II study of its ToleroMune ragweed allergy treatment. However, the product candidate is trailing behind Merck & Co/ALK-Abello's investigational ragweed and grass allergy immunotherapy which is due to be filed in 2013 (scripintelligence.com, 6 March 2012).